Literature DB >> 20926402

The tissue is the issue: personalized medicine for non-small cell lung cancer.

Fred R Hirsch1, Murry W Wynes, David R Gandara, Paul A Bunn.   

Abstract

The development of molecular markers is crucial for improving therapy in advanced non-small cell lung cancer (NSCLC). Here, we review perspectives of biomarker-driven personalized therapy in NSCLC, with particular reference to the detection of EML4-ALK gene rearrangements. Different molecular assays, validation, and clinical application to different types of tissue specimens are discussed. ©2010 AACR.

Entities:  

Mesh：

Year:  2010        PMID： 20926402     DOI： 10.1158/1078-0432.CCR-10-2005

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  22 in total

1.  Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration.

Authors:  Rex Chin Wei Yung; Susan Otell; Peter Illei; Douglas P Clark; David Feller-Kopman; Lonny Yarmus; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Cancer Cytopathol       Date:  2011-12-05       Impact factor: 5.284

2.  Drug sensitivity testing for personalized lung cancer therapy.

Authors:  Peter W Gout; Yuzhuo Wang
Journal:  J Thorac Dis       Date:  2012-02       Impact factor: 2.895

3.  Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections.

Authors:  Giuseppe Pelosi; Federica Perrone; Elena Tamborini; Alessandra Fabbri; Maria Adele Testi; Adele Busico; Giulio Settanni; Benedetta Picciani; Enrica Bovio; Angelica Sonzogni; Barbara Valeri; Marina Garassino; Filippo De Braud; Ugo Pastorino
Journal:  Virchows Arch       Date:  2016-01-27       Impact factor: 4.064

Review 4.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

Review 5.  Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?

Authors:  Silvia Calabuig-Fariñas; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Carlos Camps
Journal:  Transl Lung Cancer Res       Date:  2016-10

6.  Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.

Authors:  Francesco Gelsomino; Giulio Rossi; Marcello Tiseo
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

7.  Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.

Authors:  Cecile Bosc; Gilbert R Ferretti; Jacques Cadranel; Clarisse Audigier-Valette; Benjamin Besse; Fabrice Barlesi; Chantal Decroisette; Sylvie Lantuejoul; François Arbib; Denis Moro-Sibilot
Journal:  Target Oncol       Date:  2014-08-15       Impact factor: 4.493

8.  The potential for crizotinib in non-small cell lung cancer: a perspective review.

Authors:  Yung-Jue Bang
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

9.  Assessment of methylation status of locoregional lymph nodes in lung cancer using EBUS-NA.

Authors:  Laura Millares; Mireia Serra; Felipe Andreo; Jose Sanz-Santos; Concepción Montón; Carles Grimau; Miguel Gallego; Laia Setó; Neus Combalia; Mariona Llatjos; Rosa Escoda; Eva Castellà; Eduard Monsó
Journal:  Clin Exp Metastasis       Date:  2015-06-29       Impact factor: 5.150

10.  Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Authors:  Benjamin P Levy; Marc D Chioda; Dana Herndon; John W Longshore; Mohamed Mohamed; Sai-Hong Ignatius Ou; Craig Reynolds; Jaspal Singh; Ignacio I Wistuba; Paul A Bunn; Fred R Hirsch
Journal:  Oncologist       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.